VOGLISUG-GM-2

VOGLISUG-GM-2 is a triple-combination oral antidiabetic medication developed and marketed by Intra Life for the management of Type 2 Diabetes Mellitus. It contains three active pharmaceutical ingredients: voglibose (0.2 mg), glimepiride (2 mg), and metformin hydrochloride (1000 mg). Voglibose acts as an alpha-glucosidase inhibitor in the small intestine, delaying the digestion and absorption of carbohydrates to reduce postprandial hyperglycemia. Glimepiride is a second-generation sulfonylurea that stimulates insulin release from pancreatic beta cells by blocking ATP-sensitive potassium (KATP) channels. Metformin, a biguanide, primarily reduces hepatic glucose production through the activation of AMP-activated protein kinase (AMPK) and improves peripheral insulin sensitivity. This combination therapy is intended for patients who do not achieve adequate glycemic control with monotherapy or dual therapy.

Brand names

VOGLISUG-GM-2VOGLISUG-GM2VOGLISUG-GM 2

Other names

Voglibose + Glimepiride + Metformin Hydrochloride